Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Paraza Pharma Inc. is a North America-based drug discovery R&D service organization, rather than a typical SaaS or enterprise software product. Its official website positions it as a “fully integrated drug discovery organization,” providing outsourced R&D support from scientific strategy to research execution for pharmaceutical companies, biotech firms, academic centers, and venture capital organizations.
Its capabilities cover DMPK, in vitro ADME, pharmacokinetics and in vivo studies, bioanalysis, medicinal chemistry, chemical development, computer-aided drug design, analytical chemistry, biochemistry and biophysics, cellular pharmacology, and in vivo pharmacology. In bioanalysis, the site mentions LC-MS/MS quantitative method development, metabolite profiling, proteomics, targeted protein quantification, HDX methods, and multiple classes of instrumentation platforms. In terms of project management, the website emphasizes communication, scientific proposals, budgeting, research, timelines, and planning, indicating that its services are more oriented toward a “collaborative R&D project” model.
The website does not provide standard packages, subscription pricing, a free plan, or trial information. It only mentions “cost-effective solutions” and directs customers to get in touch to discuss specific needs. Therefore, it can be inferred that pricing is customized based on project scope, experimental requirements, timelines, and resource investment, rather than being a software product billed by seat or usage.
Paraza discloses that it is compliant with ISO/IEC 27001:2022 and uses project-level access control, data clearing/removal, multiple backups, LeapFILE secure file exchange, customer-preferred cloud servers, and internal ELN systems to protect intellectual property. This information is especially important for drug discovery projects, where customer data and compound IP are highly sensitive.
Its strengths are broad integrated disciplinary coverage, along with relevant facilities and teams in Montreal and Cambridge, making it suitable for drug discovery projects that need a North American R&D partner. Its weaknesses are that it has limited software characteristics, with no public API, developer support, third-party integration ecosystem, user permission backend, or online product experience information.
It is better suited for pharmaceutical/biotech companies, research institutions, and investment-incubated projects looking for a CRO-style R&D collaboration partner. Access from mainland China is not disclosed in the main content, so its status is unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on parazapharma.com official site.
parazapharma.com is an Canada Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach parazapharma.com directly.